BioSpace News Archive

Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the second quarter of 2023.

Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the second quarter ended June 30, 2023.

Stryker reported operating results for the second quarter of 2023.

OraSure Technologies, Inc., a leader in point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced its financial results for the three months ended June 30, 2023.

Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its second quarter 2023 financial results and provided a corporate update.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) today announced the receipt of a Study May Proceed letter from the U.S. Food and Drug Administration (FDA), for a Phase 1/2 dose escalation study of ONCT-534, a novel dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer (mCRPC) who have relapsed or are refractory to approved androgen receptor signaling inhibitors (ARSIs).

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended June 30, 2023 and provided its financial guidance for the year.

Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”) today announced its financial results for the three-month period ended June 30, 2023 (“the second quarter of 2023”) as compared to the three-month period ended June 30, 2022 (“the second quarter of 2022” or “the prior year period”).

Mesoblast Limited announced that the US Food and Drug Administration has provided a complete response to its Biologics License Application resubmission for remestemcel-L for the treatment of pediatric steroid-refractory acute graft versus host disease and requires more data to support marketing approval.

PTC Therapeutics, Inc. announced a corporate update and financial results for the second quarter ending June 30, 2023.